Breakthroughs in Cardiac Care: 20 Years of Stem Cell Innovation for Heart Health
In a recent event hosted by The Public Lead and moderated by Maya Pomroy, renowned physician-scientists Dr. Deepak Srivastava and Dr. Emerson Perin took the stage to discuss major advancements in stem cell research for cardiac care over the past two decades. This insightful conversation delves into the role of regenerative medicine in treating heart […]
Accelerating Heart Disease Research: Allen Institute’s New Disease-Specific Cell Lines
On June 4, 2024, the Allen Institute for Cell Science announced the launch of its first disease-specific cell line collections, marking a significant milestone in genetic heart disease research. This innovative set of tools, specifically designed to advance the study of hypertrophic cardiomyopathy (HCM) and other muscle disorders, represents a groundbreaking step in the quest […]
Immorta Bio Inc. Announces Breakthrough in Liver Failure Treatment with Stem Cell Technology
Immorta Bio Inc., a company focused on longevity and regenerative medicine, has announced a significant breakthrough in the treatment of liver failure. The company is developing personalized stem cell technologies that show great promise in combating various diseases of aging. Immorta Bio’s research pipeline includes Personalized Regenerative Cells (PRCs), Personalized Mesenchymal Stem Cells (pMSCs), and […]
Revolutionizing Cardiac Health: Stem Cell Innovations in Arrhythmia Treatment
Arrhythmias, irregular heartbeats disrupting the normal rhythm of the heart, pose significant health challenges, affecting millions worldwide. Amidst various treatments, stem cell therapy has emerged as a revolutionary approach in regenerative medicine, offering new hope for those suffering from this condition. At the forefront of cardiac health advancements, stem cell therapy holds the potential to […]
BioCardia Announces FDA Approval for Groundbreaking Heart Failure Treatment
BioCardia, Inc., a prominent player in the development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, has recently announced a significant milestone. The U.S. Food and Drug Administration (FDA) has approved the Phase III clinical trial protocol for BioCardia’s CardiAMP autologous cell therapy. This therapy is designed for patients suffering from ischemic heart […]
Unleashing Cardiac Stem Cells: Transforming Heart Health
Introduction Let’s dive into the incredible world of cardiac stem cells and their potential to transform the field of heart disease treatment. If you or a loved one are dealing with heart conditions, we understand the challenges you face, and we’re here to offer hope. Heart conditions can have a profound impact on individuals, affecting […]
Exploring the Benefits of MSCT for IHD
Introduction Mesenchymal Stem Cell Therapy (MSCT) is a promising, yet still experimental form of treatment that has the potential to revolutionize the management of Ischemic Heart Disease (IHD). What are Mesenchymal Stem Cells Mesenchymal stem cells (MSCs) are a type of adult stem cell found in the body that can differentiate into several different types […]
Dr. Jill interviews Dr. Chadwick Prodromos on Stem Cell Treatment and Regenerative Medicine
In episode #136, Dr. Jill Carnahan speaks with Dr. Chadwick Prodromos about the exciting developments in stem cell treatment and how it is revolutionizing our approach to disease and aging. Stem cells have the unique ability to develop into any type of cell in the body, making them a promising tool for repairing and regenerating […]
Global Stem Cells Market to Generate Revenue of $25.68 Billion By 2028 | More than 80% of Revenue Comes from Adult Stem Cells
Westford,USA, Nov. 02, 2022 (GLOBE NEWSWIRE) — The demand for stem cells market is growing rapidly as the potential for their use in medical treatments expands. In particular, there is great interest in using stem cells to treat a range of degenerative diseases and injuries, as well as to improve the success of organ transplants. Recent advances […]
BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial
SUNNYVALE, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase III pivotal CardiAMP® Cell Therapy Heart Failure Trial (clinicaltrials.gov Identifier: […]